Interestingly, we observed that BAY 87-2243 displayed increased anti-tumor efficacy compared to single agent treatment when combined with the small molecule mutant BRAF inhibitor vemurafenib in nude mice bearing BRAF mutant melanoma xenografts. Here, BRAF is linked to melanoma.